b 61

JAK1-IN-B61 is a JAK1 inhibitor.

BI-665915 is a 5-lipoxygenase activating protein inhibitor.

HSD17B13-IN-61 (Compound 132) 作为一种高效的羟基类固醇 17β-脱氢酶 13 (HSD17B13) 抑制剂，展现了极佳的抑制活性，其IC50值达到或低于 0.1 μM。该化合物主要用于研究肝病、代谢性疾病和心血管疾病，包括非酒精性脂肪肝病(NAFLD)、非酒精性脂肪肝炎(NASH)及药物性肝损伤(DILI)。

SKLB 610 是一种新型多靶点抑制剂，在生化激酶测定中，浓度为 10 μM 时，对血管生成相关酪氨酸激酶 VEGFR2、FGFR2 和 PDGFR 的抑制率分别为 97%、65% 和 55%。

CB2R激动剂, 其化学式为C25H28N6O3S，分子量为508.6 g mol。作为一种高效且具有选择性的CB2R激动剂，该化合物表现出在医疗研究中应用的潜力。其结构包含吡咯并[2,3-b]吡啶-3-胺环，与CB2受体的结合力强。在体外试验中，这种化合物的EC50值为22 nM，体现了其高度选择性。

SB 611812 是 urotensin-II (UT) 的拮抗剂，可用于心血管疾病治疗的研究。

RB 6145是一种双功能硝基咪唑，低氧细胞放射增敏剂RSU 1069的前药，它的毒性较RSU 1069降低。它具有缺氧细胞优先细胞毒性和抗肿瘤治疗活性。

M+B 6153 is a bioactive chemical.

CBLB 612是一种具有双重功效的化合物，既能作为抗辐射辅助剂，也能用作抗肿瘤剂。

SB-616234-A 是选择性的，口服有效的5-HT1B receptor 拮抗剂。SB-616234-A 具有抗焦虑和抗抑郁活性。

H3B-616是一种强效异位剂的抑制剂，针对Carbamoyl phosphate synthetase 1 (CPS1)，其IC50为66 nM。CPS1被认为是LKB1缺乏的非小细胞肺癌中的潜在合成致死靶标。在这些癌细胞中，CPS1的过表达促进了嘧啶的合成。

NOP receptor antagonist

SB-612111 is a novel and potent human opiate receptor-like orphan receptor (ORL-1) antagonist with a high affinity for hORL-1 (Ki=0.33 nM). SB-612111 exhibits selectivity for μ-, κ- and δ-receptors with Ki values of 57.6 nM, 160.5 nM and 2109 nM, respecticely. SB-612111 effectively antagonizes the pronociceptive action of Nociceptin in an acute pain model[1]. [1]. Paola F Zaratin, et al. Modification of Nociception and Morphine Tolerance by the Selective Opiate Receptor-Like Orphan Receptor Antagonist (-)-cis-1-methyl-7-[[4-(2,6-dichlorophenyl)piperidin-1-yl]methyl]-6,7,8,9-tetrahydro-5H-benzocyclohepten-5-ol (SB-612111).J Pharmacol Exp Ther. 2004 Feb;308(2):454-61.

SB-612111 hydrochloride 是一种高效的、新型的阿片受体孤儿受体 (ORL-1) 拮抗剂，对 hORL-1 具有较高的亲和力，Ki 值为 0.33 nM。SB-612111 hydrochloride 能够作用于 μ-receptor (Ki: 57.6 nM)，κ-receptor (Ki: 160.5 nM) 和 δ-receptor (Ki: 2109 nM)。SB-612111 hydrochloride 能有效拮抗 Nociceptin 在急性疼痛模型中的造成的痛觉作用。

MCB-613 是类固醇受体共激活因子 (SRC) 小分子“刺激物” (SMS)，超刺激 SRCs 的转录活性。它促进 SRC 与其他共激活因子发生相互作用，并显著诱导 ER 应激与活性氧的产生相结合。它是一种 SMS，能够过度刺激 SRC 致癌程序，靶向癌基因用作抗癌药物。

Sodium 2-mercaptobenzothiazole is the sodium salt of mercaptobenzothiazole, and is used as a copper corrosion inhibitor.

Ginisortamab (UCB6114)为全人源IgG4P抗Gremlin-1单克隆抗体，潜在应用于研究胃肠道（GI）肿瘤。

RNB-61,一种具口服活性的大麻素CB2受体 (CB2R) 激动剂,其Ki值介于0.13 nM至1.81 nM之间.该化合物显示出肾脏保护和 或抗纤维化作用,同时其对脑的渗透性极低.

Anti-MouseIL-2Antibody (S4B6-1) 是一种靶向IL-2的小鼠来源IgG2akappa类大鼠抗体。其同型对照为RatIgG2akappa, Isotype Control。

Danusertib (PHA-739358) 是一种极光激酶抑制剂，能够抑制 Aurora A、Aurora B 和 Aurora C 的活性，IC50值分别为 13、79 和 61 nM。它是一种具有潜在抗肿瘤活性的小分子 3-氨基吡唑衍生物。

Balicatib (AAE581) 是组织蛋白酶K 抑制剂，其对组织蛋白酶K 的抑制作用是组织蛋白酶B、L 和S 的抑制性的10到100倍。

AT-61 is a nonnucleoside analogue inhibitor of hepatitis B virus (HBV) replication.

CAY10736 is an anticancer compound.1 It inhibits proliferation in a panel of melanoma and breast, pancreatic, and lung cancer cell lines (IC50s = 0.827-9.89 μM). CAY10736 inhibits migration and epithelial-to-mesenchymal transition (EMT) of A375 and B16/F10 melanoma cells in vitro in a concentration-dependent manner. It reduces the viability of spheroid A375 and B16/F10 cells (IC50s = 2.4 and 1.59 μM, respectively) and increases the production of reactive oxygen species (ROS) in these cells in a concentration-dependent manner. CAY10736 (5 mg/kg) reduces tumor growth in B16/F10 melanoma and Lewis lung carcinoma mouse models and an A375 mouse xenograft model.References1. Liu, X., Li, B., Zhang, Z., et al. Synthesis and discovery novel anti-cancer stem cells compounds derived from the natural triterpenoic acids. J. Med. Chem. 61(23), 10814-10833 (2018). CAY10736 is an anticancer compound.1 It inhibits proliferation in a panel of melanoma and breast, pancreatic, and lung cancer cell lines (IC50s = 0.827-9.89 μM). CAY10736 inhibits migration and epithelial-to-mesenchymal transition (EMT) of A375 and B16/F10 melanoma cells in vitro in a concentration-dependent manner. It reduces the viability of spheroid A375 and B16/F10 cells (IC50s = 2.4 and 1.59 μM, respectively) and increases the production of reactive oxygen species (ROS) in these cells in a concentration-dependent manner. CAY10736 (5 mg/kg) reduces tumor growth in B16/F10 melanoma and Lewis lung carcinoma mouse models and an A375 mouse xenograft model. References1. Liu, X., Li, B., Zhang, Z., et al. Synthesis and discovery novel anti-cancer stem cells compounds derived from the natural triterpenoic acids. J. Med. Chem. 61(23), 10814-10833 (2018).

CAY10735 is an anticancer compound.1 It inhibits proliferation in a panel of melanoma and breast, pancreatic, and lung cancer cell lines (IC50s = 0.674-11.56 μM). CAY10735 inhibits migration of and the epithelial-to-mesenchymal transition (EMT) in A375 and B16 F10 melanoma cells in vitro in a concentration-dependent manner. It reduces the viability of spheroid A375 and B16 F10 cells (IC50s = 3.04 and 1.24 μM, respectively) and increases production of reactive oxygen species (ROS) in these cells in a concentration-dependent manner. CAY10735 (5 mg kg) reduces tumor growth in B16 F10 melanoma and Lewis lung carcinoma mouse models and an A375 mouse xenograft model.References1. Liu, X., Li, B., Zhang, Z., et al. Synthesis and discovery novel anti-cancer stem cells compounds derived from the natural triterpenoic acids. J. Med. Chem. 61(23), 10814-10833 (2018). CAY10735 is an anticancer compound.1 It inhibits proliferation in a panel of melanoma and breast, pancreatic, and lung cancer cell lines (IC50s = 0.674-11.56 μM). CAY10735 inhibits migration of and the epithelial-to-mesenchymal transition (EMT) in A375 and B16 F10 melanoma cells in vitro in a concentration-dependent manner. It reduces the viability of spheroid A375 and B16 F10 cells (IC50s = 3.04 and 1.24 μM, respectively) and increases production of reactive oxygen species (ROS) in these cells in a concentration-dependent manner. CAY10735 (5 mg kg) reduces tumor growth in B16 F10 melanoma and Lewis lung carcinoma mouse models and an A375 mouse xenograft model. References1. Liu, X., Li, B., Zhang, Z., et al. Synthesis and discovery novel anti-cancer stem cells compounds derived from the natural triterpenoic acids. J. Med. Chem. 61(23), 10814-10833 (2018).